Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration

详细信息    查看全文

• 作者：Takeshi Wada ; Masaki Kobayashi ; Yuichi Ono ; Asumi Mizugaki…
• 关键词：Levofloxacin ; Pharmacokinetics ; Continuous hemodiafiltration ; Clearance
• 刊名：Journal of Intensive Care
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：3
• 期：1
• 全文大小：501KB
• 参考文献：1.Tanigawara Y, Nomura H, Kagimoto N, Okumura K, Hori R. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull. 1995;18:315鈥?0.CrossRef PubMed
  2.Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy. 2000;46 Suppl 1:6鈥?4.CrossRef PubMed
  3.Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589鈥?6.CrossRef PubMed
  4.Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003;22:203鈥?1.PubMed
  5.Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002;22:1216鈥?5.CrossRef PubMed
  6.Hayakawa M, Ito Y, Fujita I, Iseki K, Gando S. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. ASAIO J. 2006;52:398鈥?03.CrossRef PubMed
  7.Hayakawa M, Fujita I, Iseki K, Gando S. The administration of ciprofloxacin during continuous renal replacement therapy: pilot study. ASAIO J. 2009;55:243鈥?.CrossRef PubMed
  
• 作者单位：Takeshi Wada (1)
  Masaki Kobayashi (2)
  Yuichi Ono (1)
  Asumi Mizugaki (1)
  Kenichi Katabami (1)
  Kunihiko Maekawa (1)
  Daisuke Miyamoto (1)
  Yuichiro Yanagida (1)
  Mineji Hayakawa (1)
  Atsushi Sawamura (1)
  Ken Iseki (2) (3)
  Satoshi Gando (1)
  
  1. Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo, 060-8638, Japan
  2. Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, N12W6, Kita-ku, Sapporo, 060-0812, Japan
  3. Department of Pharmacy, Hokkaido University Hospital, N14W5, Kita-ku, Sapporo, 060-8648, Japan
  
• 刊物类别：Intensive / Critical Care Medicine;
• 刊物主题：Intensive / Critical Care Medicine;
• 出版者：BioMed Central
• ISSN：2052-0492

文摘

The aim of this study was to establish the pharmacokinetics of levofloxacin (LVFX) and determine the optimal dose of this drug in critically ill patients receiving continuous hemodiafiltration (CHDF). The results of in vivo and in vitro studies showed the pharmacokinetics of LVFX total clearance (CL_total) according to the creatinine clearance (CL_Cre), dialysate flow (Q_D), and ultrafiltrate flow (Q_F), to be as follows: CL_total (l/h) = 0.0836 脳 CL_Cre (ml/min) + 0.013 脳 body weight (kg) + 0.94(Q_D + Q_F) (l/h). The optimal dose of LVFX was expressed by the following formula: 50 脳 CL_total. These results demonstrate that the usual dose of LVFX (500 mg) was sufficient for the patients evaluated in this study. Keywords Levofloxacin Pharmacokinetics Continuous hemodiafiltration Clearance